Biotech Values

[DewDiligence]

ANAB files S-1 for IPO:

http://finance.yahoo.com/news/anaptysbio-files-registration-statement-proposed-210000997.html

AnaptysBio is an antibody development company focused on novel programs in inflammation and immuno-oncology. The Company's proprietary pipeline includes ANB020, an anti-IL-33 antibody for the treatment of severe adult asthma and severe adult peanut allergy, and ANB019, an anti-IL-36 receptor antibody initially being developed for the treatment of generalized pustular psoriasis.

AnaptysBio's SHM-XEL platform has pioneered the use of in vitro somatic hypermutation for antibody discovery, which is designed to replicate key features of the human immune system and overcomes limitations of prior antibody technologies.

AnaptysBio has previously announced partnerships with several biopharmaceutical companies, including Celgene and Tesaro.